Activating transcription factor 3 (ATF3), which is encoded by an adaptive-response gene induced by various stimuli, plays an important role in the cardiovascular system. However, the effect of ATF3 on cardiac hypertrophy induced by a pathological stimulus has not been determined. Here, we investigated the effects of ATF3 deficiency on cardiac hypertrophy using in vitro and in vivo models. Aortic banding (AB) was performed to induce cardiac hypertrophy in mice. Cardiac hypertrophy was estimated by echocardiographic and hemodynamic measurements and by pathological and molecular analysis. ATF3 deficiency promoted cardiac hypertrophy, dysfunction and fibrosis after 4 weeks of AB compared to the wild type (WT) mice. Furthermore, enhanced activation of the MEK-ERK1/2 and JNK pathways was found in ATF3-knockout (KO) mice compared to WT mice. In vitro studies performed in cultured neonatal mouse cardiomyocytes confirmed that ATF3 deficiency promotes cardiomyocyte hypertrophy induced by angiotensin II, which was associated with the amplification of MEK-ERK1/2 and JNK signaling. Our results suggested that ATF3 plays a crucial role in the development of cardiac hypertrophy via negative regulation of the MEK-ERK1/2 and JNK pathways.
References
[1]
McKinsey TA, Kass DA (2007) Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov 6: 617–635.
[2]
Dorn GW 2nd (2007) The fuzzy logic of physiological cardiac hypertrophy. Hypertension 49: 962–970.
[3]
Heineke J, Molkentin JD (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7: 589–600.
[4]
Thompson MR, Xu D, Williams BR (2009) ATF3 transcription factor and its emerging roles in immunity and cancer. J Mol Med 87: 1053–1060.
[5]
Hai T, Wolfgang CD, Marsee DK, Allen AE, Sivaprasad U (1999) ATF3 and stress responses. Gene Expr 7: 321–335.
[6]
Liang G, Wolfgang CD, Chen BP, Chen TH, Hai T (1996) ATF3 gene. Genomic organization, promoter, and regulation. J Biol Chem 271: 1695–1701.
[7]
Hai T, Hartman MG (2001) The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene 273: 1–11.
[8]
Hai T, Wolford CC, Chang YS (2010) ATF3, a hub of the cellular adaptive-response network, in the pathogenesis of diseases: is modulation of inflammation a unifying component? Gene Expr 15: 1–11.
[9]
Inoue K, Zama T, Kamimoto T, Aoki R, Ikeda Y, et al. (2004) TNFalpha-induced ATF3 expression is bidirectionally regulated by the JNK and ERK pathways in vascular endothelial cells. Genes Cells 9: 59–70.
[10]
Chen SC, Liu YC, Shyu KG, Wang DL (2008) Acute hypoxia to endothelial cells induces activating transcription factor 3 (ATF3) expression that is mediated via nitric oxide. Atherosclerosis 201: 281–288.
[11]
Lv D, Meng D, Zou FF, Fan L, Zhang P, et al. (2011) Activating transcription factor 3 regulates survivability and migration of vascular smooth muscle cells. IUBMB Life 63: 62–69.
[12]
Nobori K, Ito H, Tamamori-Adachi M, Adachi S, Ono Y, et al. (2002) ATF3 inhibits doxorubicin-induced apoptosis in cardiac myocytes: a novel cardioprotective role of ATF3. J Mol Cell Cardiol 34: 1387–1397.
[13]
Okamoto Y, Chaves A, Chen J, Kelley R, Jones K, et al. (2001) Transgenic mice with cardiac-specific expression of activating transcription factor 3, a stress-inducible gene, have conduction abnormalities and contractile dysfunction. Am J Pathol 159: 639–650.
[14]
Hasin T, Elhanani O, Abassi Z, Hai T, Aronheim A (2011) Angiotensin II signaling up-regulates the immediate early transcription factor ATF3 in the left but not the right atrium. Basic Res Cardiol 106: 175–187.
[15]
Hartman MG, Lu D, Kim ML, Kociba GJ, Shukri T, et al. (2004) Role for activating transcription factor 3 in stress-induced beta-cell apoptosis. Mol Cell Biol 24: 5721–5732.
[16]
Li H, He C, Feng J, Zhang Y, Tang Q, et al. (2010) Regulator of G protein signaling 5 protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload. Proc Natl Acad Sci U S A 107: 13818–13823.
[17]
Yan L, Wei X, Tang QZ, Feng J, Zhang Y, et al. (2011) Cardiac-specific mindin overexpression attenuates cardiac hypertrophy via blocking AKT/GSK3{beta} and TGF-{beta}1-Smad signaling. Cardiovasc Res.
[18]
Nickson P, Toth A, Erhardt P (2007) PUMA is critical for neonatal cardiomyocyte apoptosis induced by endoplasmic reticulum stress. Cardiovasc Res 73: 48–56.
[19]
Kehat I, Hasin T, Aronheim A (2006) The role of basic leucine zipper protein-mediated transcription in physiological and pathological myocardial hypertrophy. Ann N Y Acad Sci 1080: 97–109.
[20]
Kehat I, Heinrich R, Ben-Izhak O, Miyazaki H, Gutkind JS, et al. (2006) Inhibition of basic leucine zipper transcription is a major mediator of atrial dilatation. Cardiovasc Res 70: 543–554.
[21]
Manabe I, Shindo T, Nagai R (2002) Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res 91: 1103–1113.
[22]
Pandya K, Kim HS, Smithies O (2006) Fibrosis, not cell size, delineates beta-myosin heavy chain reexpression during cardiac hypertrophy and normal aging in vivo. Proc Natl Acad Sci U S A 103: 16864–16869.
[23]
Hutchinson KR, Guggilam A, Cismowski MJ, Galantowicz ML, West TA, et al. (2011) Temporal pattern of left ventricular structural and functional remodeling following reversal of volume overload heart failure. J Appl Physiol.
[24]
Koitabashi N, Danner T, Zaiman AL, Pinto YM, Rowell J, et al. (2011) Pivotal role of cardiomyocyte TGF-beta signaling in the murine pathological response to sustained pressure overload. J Clin Invest.
[25]
Rose BA, Force T, Wang Y (2010) Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev 90: 1507–1546.
[26]
Muslin AJ (2008) MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci (Lond) 115: 203–218.
[27]
Huang H, Tang QZ, Wang AB, Chen M, Yan L, et al. (2010) Tumor suppressor A20 protects against cardiac hypertrophy and fibrosis by blocking transforming growth factor-beta-activated kinase 1-dependent signaling. Hypertension 56: 232–239.
[28]
Lu D, Chen J, Hai T (2007) The regulation of ATF3 gene expression by mitogen-activated protein kinases. Biochem J 401: 559–567.
[29]
St Germain C, Niknejad N, Ma L, Garbuio K, Hai T, et al. (2010) Cisplatin induces cytotoxicity through the mitogen-activated protein kinase pathways and activating transcription factor 3. Neoplasia 12: 527–538.
[30]
Tamura K, Hua B, Adachi S, Guney I, Kawauchi J, et al. (2005) Stress response gene ATF3 is a target of c-myc in serum-induced cell proliferation. EMBO J 24: 2590–2601.
[31]
Cai Y, Zhang C, Nawa T, Aso T, Tanaka M, et al. (2000) Homocysteine-responsive ATF3 gene expression in human vascular endothelial cells: activation of c-Jun NH(2)-terminal kinase and promoter response element. Blood 96: 2140–2148.
[32]
Lu D, Wolfgang CD, Hai T (2006) Activating transcription factor 3, a stress-inducible gene, suppresses Ras-stimulated tumorigenesis. J Biol Chem 281: 10473–10481.
[33]
Nakagomi S, Suzuki Y, Namikawa K, Kiryu-Seo S, Kiyama H (2003) Expression of the activating transcription factor 3 prevents c-Jun N-terminal kinase-induced neuronal death by promoting heat shock protein 27 expression and Akt activation. J Neurosci 23: 5187–5196.
[34]
Kuster GM, Pimentel DR, Adachi T, Ido Y, Brenner DA, et al. (2005) Alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes is mediated via thioredoxin-1-sensitive oxidative modification of thiols on Ras. Circulation 111: 1192–1198.
[35]
Anjum R, Blenis J (2008) The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 9: 747–758.
[36]
Dorn GW 2nd, Force T (2005) Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115: 527–537.
[37]
Gilchrist M, Henderson WR Jr, Morotti A, Johnson CD, Nachman A, et al. (2010) A key role for ATF3 in regulating mast cell survival and mediator release. Blood 115: 4734–4741.
